Hubbry Logo
Hepatocyte growth factor receptorHepatocyte growth factor receptorMain
Open search
Hepatocyte growth factor receptor
Community hub
Hepatocyte growth factor receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hepatocyte growth factor receptor
Hepatocyte growth factor receptor
Hepatocyte growth factor receptor
View on Wikipedia
from Wikipedia

MET
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesMET, MET proto-oncogene, receptor tyrosine kinase, AUTS9, HGFR, RCCP2, c-Met, DFNB97, OSFD, c-met
External IDsOMIM: 164860; MGI: 96969; HomoloGene: 206; GeneCards: MET; OMA:MET - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4233

17295

Ensembl

ENSG00000105976

ENSMUSG00000009376

UniProt

P08581

P16056

RefSeq (mRNA)

NM_000245
NM_001127500
NM_001324401
NM_001324402

NM_008591

RefSeq (protein)

NP_000236
NP_001120972
NP_001311330
NP_001311331

n/a

Location (UCSC)Chr 7: 116.67 – 116.8 MbChr 6: 17.46 – 17.57 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Hepatocyte growth factor receptor (HGF receptor)[5][6] is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity.[7] The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.

HGF receptor is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Hepatocyte growth factor/scatter factor (HGF/SF) and its splicing isoform (NK1, NK2) are the only known ligands of the HGF receptor.[citation needed] MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. When HGF/SF binds its cognate receptor MET it induces its dimerization through a not yet completely understood mechanism leading to its activation.

Sometimes MET is misunderstood as of an abbreviation of mesenchymal-epithelial transition. It is incorrect. The three letters of MET come from N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).[8]

Abnormal MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express MET, which allows these cells to grow invasively in order to generate new tissues in an embryo or regenerate damaged tissues in an adult. However, cancer stem cells are thought to hijack the ability of normal stem cells to express MET, and thus become the cause of cancer persistence and spread to other sites in the body. Both the overexpression of Met/HGFR, as well as its autocrine activation by co-expression of its hepatocyte growth factor ligand, have been implicated in oncogenesis.[9][10]

Various mutations in the MET gene are associated with papillary renal carcinoma.[11]

Gene

[edit]

MET proto-oncogene (GeneID: 4233) has a total length of 125,982 bp, and it is located in the 7q31 locus of chromosome 7.[12] MET is transcribed into a 6,641 bp mature mRNA, which is then translated into a 1,390 amino-acid MET protein.

Protein

[edit]

MET is a receptor tyrosine kinase (RTK) that is produced as a single-chain precursor. The precursor is proteolytically cleaved at a furin site to yield a highly glycosylated extracellular α-subunit and a transmembrane β-subunit, which are linked together by a disulfide bridge.[13]

Extracellular

[edit]
  • Region of homology to semaphorins (Sema domain), which includes the full α-chain and the N-terminal part of the β-chain
  • Cysteine-rich MET-related sequence (MRS domain)
  • Glycine-proline-rich repeats (G-P repeats)
  • Four immunoglobulin-like structures (Ig domains), a typical protein-protein interaction region.[13]

Intracellular

[edit]

A juxtamembrane segment that contains:

  • A serine residue (Ser 985), which inhibits the receptor kinase activity upon phosphorylation[14]
  • A tyrosine residue (Tyr 1003), which is responsible for MET polyubiquitination, endocytosis, and degradation upon interaction with the ubiquitin ligase CBL[15]
  • Tyrosine kinase domain, which mediates MET biological activity. Following MET activation, transphosphorylation occurs on Tyr 1234 and Tyr 1235
  • C-terminal region contains two crucial tyrosines (Tyr 1349 and Tyr 1356), which are inserted into the multisubstrate docking site, capable of recruiting downstream adapter proteins with Src homology-2 (SH2) domains.[16] The two tyrosines of the docking site have been reported to be necessary and sufficient for the signal transduction both in vitro.[16][17]

MET signaling pathway

[edit]

MET activation by its ligand HGF induces MET kinase catalytic activity, which triggers transphosphorylation of the tyrosines Tyr 1234 and Tyr 1235. These two tyrosines engage various signal transducers,[18] thus initiating a whole spectrum of biological activities driven by MET, collectively known as the invasive growth program. The transducers interact with the intracellular multisubstrate docking site of MET either directly, such as GRB2, SHC,[19] SRC, and the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K),[19] or indirectly through the scaffolding protein Gab1[20]

Tyr 1349 and Tyr 1356 of the multisubstrate docking site are both involved in the interaction with GAB1, SRC, and SHC, while only Tyr 1356 is involved in the recruitment of GRB2, phospholipase C γ (PLC-γ), p85, and SHP2.[21]

GAB1 is a key coordinator of the cellular responses to MET and binds the MET intracellular region with high avidity, but low affinity.[22] Upon interaction with MET, GAB1 becomes phosphorylated on several tyrosine residues which, in turn, recruit a number of signalling effectors, including PI3K, SHP2, and PLC-γ. GAB1 phosphorylation by MET results in a sustained signal that mediates most of the downstream signaling pathways.[23]

Activation of signal transduction

[edit]

MET engagement activates multiple signal transduction pathways:

Role in development

[edit]

MET mediates a complex program known as invasive growth.[27] Activation of MET triggers mitogenesis, and morphogenesis.[32][33]

During embryonic development, transformation of the flat, two-layer germinal disc into a three-dimensional body depends on transition of some cells from an epithelial phenotype to spindle-shaped cells with motile behaviour, a mesenchymal phenotype. This process is referred to as epithelial-mesenchymal transition (EMT).[34] Later in embryonic development, MET is crucial for gastrulation, angiogenesis, myoblast migration, bone remodeling, and nerve sprouting among others.[35] MET is essential for embryogenesis, because MET −/− mice die in utero due to severe defects in placental development.[36] Along with Ectodysplasin A, it has been shown to be involved in the differentiation of anatomical placodes, precursors of scales, feathers and hair follicles in vertebrates.[37] Furthermore, MET is required for such critical processes as liver regeneration and wound healing during adulthood.[27]

HGF/MET axis is also involved in myocardial development. Both HGF and MET receptor mRNAs are co-expressed in cardiomyocytes from E7.5, soon after the heart has been determined, to E9.5. Transcripts for HGF ligand and receptor are first detected before the occurrence of cardiac beating and looping, and persist throughout the looping stage, when heart morphology begins to elaborate.[38] In avian studies, HGF was found in the myocardial layer of the atrioventricular canal, in a developmental stage in which the epithelial to mesenchymal transformation (EMT) of the endocardial cushion occurs.[39] However, MET is not essential for heart development, since α-MHCMet-KO mice show normal heart development.[40]

Expression

[edit]

Tissue distribution

[edit]

MET is normally expressed by epithelial cells.[27] However, MET is also found on endothelial cells, neurons, hepatocytes, hematopoietic cells, melanocytes and neonatal cardiomyocytes.[33][41] HGF expression is restricted to cells of mesenchymal origin.[34]

Transcriptional control

[edit]

MET transcription is activated by HGF and several growth factors.[42] MET promoter has four putative binding sites for Ets, a family of transcription factors that control several invasive growth genes.[42] ETS1 activates MET transcription in vitro.[43] MET transcription is activated by hypoxia-inducible factor 1 (HIF1), which is activated by low concentration of intracellular oxygen.[44] HIF1 can bind to one of the several hypoxia response elements (HREs) in the MET promoter.[34] Hypoxia also activates transcription factor AP-1, which is involved in MET transcription.[34]

Clinical significance

[edit]

Role in cancer

[edit]

MET pathway plays an important role in the development of cancer through:

Coordinated down-regulation of both MET and its downstream effector extracellular signal-regulated kinase 2 (ERK2) by miR-199a* may be effective in inhibiting not only cell proliferation but also motility and invasive capabilities of tumor cells.[46]

MET amplification has emerged as a potential biomarker of the clear cell tumor subtype.[47]

The amplification of the cell surface receptor MET often drives resistance to anti-EGFR therapies in colorectal cancer.[48]

Role in autism

[edit]

The SFARIgene database lists MET with an autism score of 2.0, which indicates that it is a strong candidate for playing a role in cases of autism. The database also identifies at least one study that found a role for MET in cases of schizophrenia. The gene was first implicated in autism in a study that identified a polymorphism in the promoter of the MET gene.[49] The polymorphism reduces transcription by 50%. Further, the variant as an autism risk polymorphism has been replicated, and shown to be enriched in children with autism and gastrointestinal disturbances.[50] A rare mutation has been found that appears in two family members, one with autism and the other with a social and communication disorder.[51] The role of the receptor in brain development is distinct from its role in other developmental processes. Activation of the MET receptor regulates synapse formation[52][53][54][55][56] and can impact the development and function of circuits involved in social and emotional behavior.[57]

Role in heart function

[edit]

In adult mice, MET is required to protect cardiomyocytes by preventing age-related oxidative stress, apoptosis, fibrosis and cardiac dysfunction.[40] Moreover, MET inhibitors, such as crizotinib or PF-04254644, have been tested by short-term treatments in cellular and preclinical models, and have been shown to induce cardiomyocytes death through ROS production, activation of caspases, metabolism alteration and blockage of ion channels.[58][59]

In the injured heart, HGF/MET axis plays important roles in cardioprotection by promoting pro-survival (anti-apoptotic and anti-autophagic) effects in cardiomyocytes, angiogenesis, inhibition of fibrosis, anti-inflammatory and immunomodulatory signals, and regeneration through activation of cardiac stem cells.[60][61]

Interaction with tumour suppressor genes

[edit]

PTEN

[edit]

PTEN (phosphatase and tensin homolog) is a tumor suppressor gene encoding a protein PTEN, which possesses lipid and protein phosphatase-dependent as well as phosphatase-independent activities.[62] PTEN protein phosphatase is able to interfere with MET signaling by dephosphorylating either PIP3 generated by PI3K, or the p52 isoform of SHC. SHC dephosphorylation inhibits recruitment of the GRB2 adapter to activated MET.[30]

VHL

[edit]

There is evidence of correlation between inactivation of VHL tumor suppressor gene and increased MET signaling in renal cell carcinoma (RCC) and also in malignant transformations of the heart.[63][64]

Cancer therapies targeting HGF/MET

[edit]

Since tumor invasion and metastasis are the main cause of death in cancer patients, interfering with MET signaling appears to be a promising therapeutic approach. A comprehensive list of HGF and MET targeted experimental therapeutics for oncology now in human clinical trials can be found here.

MET kinase inhibitors

[edit]
Further information: c-Met inhibitor

Kinase inhibitors are low molecular weight molecules that prevent ATP binding to MET, thus inhibiting receptor transphosphorylation and recruitment of the downstream effectors. The limitations of kinase inhibitors include the facts that they only inhibit kinase-dependent MET activation, and that none of them is fully specific for MET.

  • K252a (Fermentek Biotechnology) is a staurosporine analogue isolated from Nocardiopsis sp. soil fungi, and it is a potent inhibitor of all receptor tyrosine kinases (RTKs). At nanomolar concentrations, K252a inhibits both the wild type and the mutant (M1268T) MET function.[65]
  • SU11274 (SUGEN) specifically inhibits MET kinase activity and its subsequent signaling. SU11274 is also an effective inhibitor of the M1268T and H1112Y MET mutants, but not the L1213V and Y1248H mutants.[66] SU11274 has been demonstrated to inhibit HGF-induced motility and invasion of epithelial and carcinoma cells.[67]
  • PHA-665752 (Pfizer) specifically inhibits MET kinase activity, and it has been demonstrated to represses both HGF-dependent and constitutive MET phosphorylation.[68] Furthermore, some tumors harboring MET amplifications are highly sensitive to treatment with PHA-665752.[69]
  • Tivantinib (ArQule) is a promising selective inhibitor of MET, which entered a phase 2 clinical trial in 2008. (Failed a phase 3 in 2017)
  • Foretinib (XL880, Exelixis) targets multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets of foretinib are MET, VEGFR2, and KDR. Foretinib has completed a phase 2 clinical trials with indications for papillary renal cell carcinoma, gastric cancer, and head and neck cancer[citation needed]
  • SGX523 (SGX Pharmaceuticals) specifically inhibits MET at low nanomolar concentrations.
  • MP470 (SuperGen) is a novel inhibitor of c-KIT, MET, PDGFR, Flt3, and AXL. Phase I clinical trial of MP470 had been announced in 2007.
  • Vebreltinib, approved in China for the treatment of non-small-cell lung cancer.[70]

HGF inhibitors

[edit]

Since HGF is the only known ligand of MET,[citation needed] blocking the formation of a HGF:MET complex blocks MET biological activity. For this purpose, truncated HGF, anti-HGF neutralizing antibodies, and an uncleavable form of HGF have been utilized so far. The major limitation of HGF inhibitors is that they block only HGF-dependent MET activation.

  • NK4 competes with HGF as it binds MET without inducing receptor activation, thus behaving as a full antagonist. NK4 is a molecule bearing the N-terminal hairpin and the four kringle domains of HGF. Moreover, NK4 is structurally similar to angiostatins, which is why it possesses anti-angiogenic activity.[71]
  • Neutralizing anti-HGF antibodies were initially tested in combination, and it was shown that at least three antibodies, acting on different HGF epitopes, are necessary to prevent MET tyrosine kinase activation.[72] More recently, it has been demonstrated that fully human monoclonal antibodies can individually bind and neutralize human HGF, leading to regression of tumors in mouse models.[73] Two anti-HGF antibodies are currently available: the humanized AV299 (AVEO), and the fully human AMG102 (Amgen).
  • Uncleavable HGF is an engineered form of pro-HGF carrying a single amino-acid substitution, which prevents the maturation of the molecule. Uncleavable HGF is capable of blocking MET-induced biological responses by binding MET with high affinity and displacing mature HGF. Moreover, uncleavable HGF competes with the wild-type endogenous pro-HGF for the catalytic domain of proteases that cleave HGF precursors. Local and systemic expression of uncleavable HGF inhibits tumor growth and, more importantly, prevents metastasis.

Decoy MET

[edit]

Decoy MET refers to a soluble truncated MET receptor. Decoys are able to inhibit MET activation mediated by both HGF-dependent and independent mechanisms, as decoys prevent both the ligand binding and the MET receptor homodimerization. CGEN241 (Compugen) is a decoy MET that is highly efficient in inhibiting tumor growth and preventing metastasis in animal models.[74]

Immunotherapy targeting MET

[edit]

Drugs used for immunotherapy can act either passively by enhancing the immunologic response to MET-expressing tumor cells, or actively by stimulating immune cells and altering differentiation/growth of tumor cells.[75]

Passive immunotherapy

[edit]

Administering monoclonal antibodies (mAbs) is a form of passive immunotherapy. MAbs facilitate destruction of tumor cells by complement-dependent cytotoxicity (CDC) and cell-mediated cytotoxicity (ADCC). In CDC, mAbs bind to specific antigen, leading to activation of the complement cascade, which in turn leads to formation of pores in tumor cells. In ADCC, the Fab domain of a mAb binds to a tumor antigen, and Fc domain binds to Fc receptors present on effector cells (phagocytes and NK cells), thus forming a bridge between an effector and a target cells. This induces the effector cell activation, leading to phagocytosis of the tumor cell by neutrophils and macrophages. Furthermore, NK cells release cytotoxic molecules, which lyse tumor cells.[75]

  • DN30 is monoclonal anti-MET antibody that recognizes the extracellular portion of MET. DN30 induces both shedding of the MET ectodomain as well as cleavage of the intracellular domain, which is successively degraded by proteasome machinery. As a consequence, on one side MET is inactivated, and on the other side the shed portion of extracellular MET hampers activation of other MET receptors, acting as a decoy. DN30 inhibits tumour growth and prevents metastasis in animal models.[76]
  • OA-5D5 is one-armed monoclonal anti-MET antibody that was demonstrated to inhibit orthotopic pancreatic[77] and glioblastoma[78] tumor growth and to improve survival in tumor xenograft models. OA-5D5 is produced as a recombinant protein in Escherichia coli. It is composed of murine variable domains for the heavy and light chains with human IgG1 constant domains. The antibody blocks HGF binding to MET in a competitive fashion.

Active immunotherapy

[edit]

Active immunotherapy to MET-expressing tumors can be achieved by administering cytokines, such as interferons (IFNs) and interleukins (IL-2), which triggers non-specific stimulation of numerous immune cells. IFNs have been tested as therapies for many types of cancers and have demonstrated therapeutic benefits. IL-2 has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma and metastatic melanoma, which often have deregulated MET activity.[75]

Interactions

[edit]

Met has been shown to interact with:

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Hepatocyte growth factor receptor

View on Grokipedia
from Grokipedia
The hepatocyte growth factor , commonly known as c-MET or MET, is a single-pass transmembrane encoded by the MET proto-oncogene located on 7q31, which specifically binds the hepatocyte growth factor (HGF)—also termed scatter factor—to initiate signaling cascades that control epithelial cell proliferation, survival, motility, and morphogenesis during development and tissue repair. Structurally, c-MET is synthesized as a 150 kDa precursor polypeptide that undergoes to 170 kDa and proteolytic cleavage into disulfide-linked α (50 kDa) and β (140 kDa) chains, forming a heterodimer with an extracellular domain comprising a semaphorin (SEMA) region for binding, a plexin-semaphorin-integrin (PSI) module, four immunoglobulin-like plexin-transcription factor (IPT) domains, a single transmembrane helix, and an intracellular portion including a juxtamembrane region and a (TK) domain. HGF, its sole , is produced as an inactive 90 kDa single-chain precursor by mesenchymal cells and activated through proteolytic processing into a bioactive heterodimer consisting of an α-chain (with an N-terminal hairpin and four domains) and a serine protease-like β-chain, enabling . Upon HGF binding, c-MET undergoes dimerization, leading to autophosphorylation of key residues (Y1234/Y1235 in the loop and Y1349/Y1356 in the C-terminal tail), which recruits adaptor proteins like , Gab1, PI3K, and to activate downstream pathways including MAPK/ERK (for proliferation), PI3K/AKT (for survival), and FAK/Src (for ). In normal physiology, c-MET signaling is indispensable for embryonic development—such as myogenesis, liver and placenta formation—and adult tissue regeneration, particularly in the liver following injury, where it promotes hepatocyte proliferation and inhibits apoptosis to facilitate repair. Dysregulation of c-MET, through mechanisms like gene amplification, overexpression, or activating mutations (e.g., in the TK domain for papillary renal carcinoma or juxtamembrane for lung cancer), transforms it into an oncogene that drives tumor invasion, metastasis, and resistance to therapy in various malignancies, including gastric, lung, and hepatocellular carcinomas, making it a prominent therapeutic target for inhibitors such as tyrosine kinase inhibitors (e.g., cabozantinib) and monoclonal antibodies. As of 2025, additional MET-targeted therapies, including combinations of tyrosine kinase inhibitors with EGFR inhibitors, have been approved for specific cancers such as non-small cell lung cancer.

Genetics

Gene Structure

The MET proto-oncogene, encoding the hepatocyte growth factor receptor (also known as c-MET), is located on the long arm of human chromosome 7 at the 7q31.2 locus. It spans approximately 125 kb of genomic DNA and consists of 21 exons interrupted by 20 introns, with exon sizes ranging from 81 bp (exon 16) to 2.5 kb (exon 21). All exons are flanked by canonical GT-AG dinucleotide splice sites at the 5' and 3' boundaries, respectively. Exon 1 is entirely non-coding and contains most of the 5' untranslated region (UTR), while exon 2 is the largest internal coding exon at 1214 nucleotides and includes the ATG start codon for the receptor protein. The genomic organization of MET reflects its functional domains, with exons 2 through 13 encoding the extracellular and transmembrane regions, and exons 14 through 21 specifying the intracellular tyrosine kinase domain, which spans about 30 kb of genomic sequence. Exon 21, the largest, encodes the carboxy-terminal tail and a long 3' UTR. Specific nucleotide motifs within the kinase domain-encoding exons include conserved sequences critical for ATP binding and phosphotransfer, such as the glycine-rich loop in exon 15 and the activation loop in exon 19. Alternative splicing of the MET pre-mRNA generates multiple isoforms, including the full-length transcript (isoform a, NM_001127500.3) and shorter variants such as isoform b (NM_000245.4), which lacks part of the beta chain, and isoform c (NM_001324401.3), a truncated form missing the intracellular domain. Notable splicing events include frequent skipping of 2, producing a ubiquitous 7 kb transcript with no detectable protein product, and exclusion of 13, yielding a Δ13MET isoform predominantly expressed in human liver that alters binding. These isoforms arise from -intron boundary recognition by splicing factors, with no evidence of complex alternative promoter usage in the wild-type . The MET gene exhibits strong evolutionary conservation across mammalian species, with orthologs identified in , , and other mammals showing over 85% nucleotide sequence identity in the coding regions, particularly in the domain exons. This homology underscores the essential role of MET in developmental and regenerative processes, as evidenced by functional conservation in and models.

Mutations and Variants

The MET gene, encoding the hepatocyte growth factor receptor (also known as c-MET), harbors various and somatic mutations that drive oncogenesis across multiple cancer types. variants are primarily associated with hereditary (HPRC), an autosomal dominant disorder characterized by multifocal and bilateral type 1 papillary renal tumors. These variants consist of missense mutations clustered in the domain, such as M1149T, V1206L, V1238I, D1246N, and Y1248C, which flank the activation loop tyrosines Y1234 and Y1235. These mutations result in constitutive activation of the MET receptor, promoting uncontrolled and tumor formation even in the heterozygous state. Somatic mutations in MET occur in both the juxtamembrane and domains, contributing to tumorigenesis in sporadic cancers. In the domain, activating missense like Y1230C and D1246N enhance receptor activity by mimicking autophosphorylation at key tyrosines, leading to ligand-independent signaling and increased cell and . The Y1230C has been identified in metastases, while D1246N appears in colorectal cancers and confers resistance to MET inhibitors in non-small cell (NSCLC). Overall somatic MET prevalence is approximately 5.6% in NSCLC and up to 8% in adenocarcinomas, with lower rates in other tumors such as 3% in squamous cell cancers and 7-9% in advanced or ovarian cancers. A prominent activating alteration is MET exon 14 skipping (MET∆14), which results from mutations or deletions in splice sites flanking exon 14, leading to loss of a juxtamembrane tyrosine (Y1003) critical for receptor ubiquitination and degradation. This impairs c-Cbl-mediated downregulation, causing MET protein accumulation, enhanced stability, and constitutive signaling that promotes tumor cell survival and metastasis. MET∆14 occurs in 2-4% of NSCLC cases, with a median frequency of 2.0% across unselected patients and higher rates (up to 12%) in sarcomatoid histology; it is rare in other drivers like EGFR mutations. Gene amplification represents another key oncogenic variant, involving increased MET copy numbers that drive overexpression and hypersensitivity to hepatocyte growth factor. In NSCLC, MET amplification is detected in 3-5% of cases, particularly among patients with acquired resistance to EGFR inhibitors (up to 20% of such cases), and correlates with aggressive disease progression through sustained downstream pathway activation. Polymorphisms in MET, such as single variants in non-coding regions, have been linked to modest risks for certain cancers but lack the strong oncogenic potential of the above alterations. These genetic changes collectively underscore MET's role as a therapeutic target, with downstream effects including hyperactivation of PI3K/AKT and MAPK pathways that fuel tumor growth.

Protein Structure

Extracellular Domain

The extracellular domain of the hepatocyte growth factor receptor (MET), also known as c-MET, consists of a disulfide-linked α-β heterodimer derived from proteolytic processing of a single-chain precursor. This cleavage occurs between Arg307 and Ser308, yielding an α-chain of approximately 32 (residues 25–307 of the mature protein) and a β-chain of about 120 (residues 308–932). The α-chain encompasses the N-terminal portion of the Sema domain, while the β-chain includes the C-terminal Sema region, the PSI domain, and four immunoglobulin-like plexin-transcription factor (IPT) domains; at least three interchain bonds, such as Cys282-Cys409 and Cys298-Cys363, covalently link the chains to maintain structural integrity. The Sema domain, spanning residues 25–515, forms a seven-bladed β-propeller fold characteristic of semaphorin family members and serves as the primary site for growth factor (HGF) binding. This domain adopts a compact structure stabilized by seven intrachain disulfide bonds, with the bottom face of blades 2 and 3 directly interacting with the serine protease-like β-chain of HGF to initiate recognition. Key residues within the Sema domain, including His296 and Tyr295, contribute to this high-affinity interaction by forming hydrogen bonds and hydrophobic contacts with HGF, as revealed in crystallographic studies. Adjacent to the Sema domain, the PSI (plexin-semaphorin-integrin) domain (residues 516–562) comprises approximately 50 amino acids rich in residues, forming four bonds that rigidify the linker region between the Sema and IPT domains. This domain plays a crucial role in stabilizing the overall extracellular architecture, facilitating proper orientation for ligand-induced dimerization without directly participating in HGF binding; flexibility at the Sema-PSI junction, conferred by Gly517 and Gly519, allows conformational adjustments during . The four C-terminal IPT domains (IPT1–4, spanning roughly residues 563–932) exhibit immunoglobulin-like folds akin to plexin-WD motifs and mediate receptor dimerization essential for signaling initiation. Specifically, IPT3 and IPT4 provide a high-affinity for the HGF α-chain, complementing the low-affinity Sema interaction to promote full heterodimerization of MET receptors upon HGF engagement. The extracellular domain features multiple N-linked sites, primarily in the Sema and IPT regions, which support proper and trafficking but do not significantly alter HGF binding affinity when removed . These glycans, numbering up to nine in the full extracellular portion, enhance and may modulate accessibility indirectly through conformational effects. Crystal structures, such as the HGF β-chain complex with the Sema-PSI domains (PDB: 1SHY), illustrate these features at 2.6 Å resolution, highlighting the disulfide-rich and binding interface.

Transmembrane and Intracellular Domains

The hepatocyte growth factor receptor, known as MET, features a single transmembrane helix spanning residues 933–955, which anchors the receptor in the plasma membrane and promotes dimerization in response to ligand binding through motifs such as GxxxG that mediate helix-helix interactions. This hydrophobic alpha-helical segment, approximately 23 amino acids long, transmits conformational changes from the extracellular domain to the intracellular region upon hepatocyte growth factor (HGF) engagement, facilitating receptor activation without direct enzymatic function. Adjacent to the transmembrane lies the intracellular juxtamembrane domain, encompassing residues 956–1077, which serves as a regulatory hub containing key residues like Y1003. Phosphorylation of Y1003 recruits the E3 ubiquitin ligase CBL, triggering ubiquitination of MET and directing the receptor toward lysosomal degradation to attenuate signaling and prevent prolonged activation. This domain's length and composition, including a conserved DpYR motif, also contribute to inhibitory interactions that fine-tune activity prior to full receptor stimulation. The core of MET's intracellular signaling resides in the tyrosine kinase domain, spanning residues 1078–1343, a catalytic region responsible for phosphorylating downstream substrates upon activation. Within the activation loop of this domain, tyrosines Y1234 and Y1235 undergo autophosphorylation, which stabilizes an open conformation of the and enhances catalytic efficiency, representing a critical step in transducing HGF-induced signals. Mutations or dysregulation in this domain can lead to constitutive activity, underscoring its role in both physiological and pathological contexts. The C-terminal tail, comprising residues 1344–1390, extends beyond the kinase domain and harbors multifunctional docking sites that recruit adaptor proteins to propagate signals. of specific motifs, such as Y1349 and Y1356, creates binding platforms for effectors like the p85 subunit of PI3K at Y1349 and at Y1356, enabling diverse downstream cascades while the tail's autoinhibitory interactions are relieved during activation. This short regulatory segment ensures signal specificity and termination through its integration with degradation pathways.

Expression and Regulation

Tissue Distribution

The hepatocyte growth factor receptor, encoded by the MET gene, exhibits high expression primarily in epithelial cells of several key organs, including the liver, , , and . According to GTEx RNA-seq data, MET shows elevated transcript levels in these tissues, with the liver displaying among the highest median TPM values across adult human samples, followed closely by and epithelia. In the placenta, MET is prominently expressed in cells, supporting roles in placental development and function, as demonstrated by RT-PCR and studies showing robust mRNA presence in villous trophoblasts. During development, MET expression peaks prominently during embryogenesis, particularly in branching organs such as the and , where it facilitates epithelial and ureteric bud branching. In embryos, reveals strong MET transcripts in epithelial cells of the developing , , and liver from embryonic day 11 onward, correlating with critical phases of . This pattern underscores MET's conserved role in epithelial proliferation and migration during fetal tissue formation. In adults, MET maintains expression in stem cell niches, such as mesenchymal stem cells in and muscle cells, and is upregulated during processes in skin and other tissues to promote repair and regeneration. The full-length isoform predominates in epithelial contexts, enabling full signaling capacity, whereas truncated isoforms appear more restricted in non-epithelial cells. Expression patterns of MET are highly conserved across species, with models recapitulating tissue distribution; for instance, GTEx-equivalent analyses in mice show elevated MET in liver, , and epithelia, as well as similar developmental upregulation in branching organs.

Transcriptional and Post-transcriptional Control

The MET gene promoter features specific elements that facilitate binding by key transcription factors to regulate its expression. SP1 binds to GC-rich motifs within the promoter to drive basal transcription, while ETS family transcription factors recognize Ets-binding sites to enhance MET expression in various cellular contexts. motifs (CANNTG sequences) in the promoter are targeted by basic helix-loop-helix transcription factors, such as MITF, which upregulate MET in melanocytes and related lineages. In cancer, hypoxic environments activate the hypoxia-inducible factor (HIF-1), which binds to multiple hypoxia response elements (HREs) in the MET promoter, inducing transcriptional activation and supporting tumor invasion and . Epigenetic mechanisms, particularly histone modifications, provide an additional layer of transcriptional control over MET. Acetylation of histones at the MET promoter, mediated by histone acetyltransferases, correlates with euchromatin formation and elevated gene expression during embryonic development and in aggressive cancers, where it facilitates MET overexpression. This modification contrasts with repressive marks like DNA hypermethylation, which can silence the locus in normal tissues. Post-transcriptional regulation fine-tunes MET mRNA levels and processing. The miR-34 family of microRNAs, transcriptionally activated by , directly targets conserved sites in the 3' (3'UTR) of MET mRNA, promoting its degradation and translational inhibition to maintain low MET levels in non-transformed cells. Dysregulation of miR-34 in cancers relieves this suppression, contributing to MET accumulation. of the MET pre-mRNA results in inclusion of exon 14, encoding the juxtamembrane domain critical for receptor ubiquitination and turnover; variants with exon 14 inclusion predominate in normal physiology, while skipping generates stable oncogenic isoforms.

Signaling Pathways

Activation Mechanism

The activation of the hepatocyte growth factor receptor (MET) is initiated by the binding of its , hepatocyte growth factor (HGF), which is secreted as an inactive single-chain precursor known as pro-HGF. Pro-HGF requires proteolytic processing to its mature two-chain form (α-chain and β-chain linked by a bond) to enable high-affinity binding to MET. This cleavage is primarily mediated by hepatocyte growth factor activator (HGFA), a that recognizes and cleaves the Arg-Val bond in pro-HGF, converting it into bioactive HGF; other proteases such as matriptase and hepsin can contribute under specific conditions, but HGFA is the dominant activator in physiological contexts. Mature HGF binds to the extracellular domain of MET, which consists of an α-chain (primarily the Sema and PSI domains) and a β-chain (including the Ig-like domains), linked by bonds following proteolytic maturation of pro-MET. The HGF α-chain engages the high-affinity site on the MET Sema domain, while the HGF β-chain, resembling a domain, interacts with the low-affinity site spanning the Sema and PSI domains, inducing a conformational rearrangement that promotes MET dimerization. This ligand-induced dimerization assembles a 2:2 HGF-MET complex, where one HGF molecule bridges two MET receptors, bringing the intracellular domains into proximity for trans-autophosphorylation. Cryo-electron structures reveal that this binding stabilizes an asymmetric dimer interface, facilitating the necessary orientation for without direct contact between the kinase domains in the extracellular assembly. Upon dimerization, the MET kinase domains undergo through autophosphorylation of tandem residues Y1234 and Y1235 within the loop of the catalytic core, which repositions the loop to open the and enhance ATP binding and phosphotransfer efficiency. This initial event further enables sequential autophosphorylation of tyrosines Y1349 and Y1356 in the C-terminal tail, generating multimolecular docking sites for downstream adaptor proteins. Structural analyses indicate that these conformational changes in the kinase domain, including loop reorientation, are directly coupled to the extracellular dimerization signal, ensuring rapid signal initiation upon HGF engagement. Computational modeling supports that HGF binding stabilizes these intracellular shifts, with the loop adopting an active DFG-in conformation essential for .

Downstream Signaling Cascades

Upon ligand-induced autophosphorylation, the hepatocyte growth factor receptor (MET) activates multiple downstream signaling cascades through its C-terminal docking sites, primarily involving the phosphotyrosines Y1349 and Y1356. These sites recruit adaptor proteins that initiate pathways promoting cell survival, proliferation, and . The PI3K/AKT pathway is activated when the adaptor protein GAB1 binds to phosphorylated Y1349 on MET, either directly or indirectly via , recruiting the p85 regulatory subunit of PI3K. This leads to PI3K activation, PIP3 production, and subsequent phosphorylation of AKT, which inhibits pro-apoptotic proteins like BAD and FOXO, thereby enhancing cell survival. Recent studies, including those on MET exon 14 skipping variants, underscore AKT's pivotal role in driving ligand-dependent invasive growth, a process involving epithelial-mesenchymal transition and sustained in cancers such as non-small cell lung cancer. The MAPK/ERK pathway is initiated by the binding of the GRB2-SOS complex to phosphorylated Y1356 on MET, which activates the SOS to stimulate RAS. This triggers the sequential activation of RAF, MEK, and ERK kinases, culminating in ERK nuclear translocation and induction of genes that drive and migration. STAT3 is directly phosphorylated by MET at tyrosine 705 following receptor activation, independent of the canonical JAK pathway, leading to STAT3 dimerization, nuclear translocation, and transcription of anti-apoptotic genes such as and MCL1. This direct interaction contributes to MET-mediated protection against and invasive phenotypes in tumor cells. MET signaling exhibits crosstalk with other receptor tyrosine kinases, notably EGFR, where EGFR activation can transphosphorylate MET, amplifying shared downstream effectors like PI3K/AKT and MAPK/ERK to enhance oncogenic signaling in cancers such as and tumors. Additionally, HGF stimulation induces upregulation of SOCS1, which acts as a regulator by promoting MET ubiquitination and proteasomal degradation, thereby attenuating sustained signaling.

Physiological Functions

Role in Development

The hepatocyte growth factor receptor (MET) plays an essential role in embryonic by mediating interactions between allantoic and trophoblastic , which are critical for placental . In MET knockout mice, homozygous mutants exhibit embryonic lethality between embryonic days 13.5 and 16.5, primarily due to severe placental defects characterized by a marked reduction in labyrinthine cells and impaired vascularization, leading to insufficient nutrient and for the . Additionally, these mutants display hypoplastic liver development, with the embryonic liver being significantly smaller and showing disorganized organization. MET is pivotal in branching tubulogenesis during the formation of epithelial organs such as the and . In , HGF binding to MET on ureteric epithelial cells induces invasive growth and iterative branching, which is fundamental for metanephric induction and subsequent formation; conditional MET inactivation in the ureteric lineage results in reduced branching and fewer nephrons. Similarly, in the , HGF/MET signaling promotes mesenchymal-derived morphogenetic cues that drive epithelial budding and elongation, ensuring proper alveolar and bronchial structure; disruption of this pathway impairs fetal lung branching . MET facilitates cell migration and through targeted expression in somites and migratory populations. During , MET is expressed in condensing somites, where HGF/MET signaling regulates the , migration, and proliferation of myogenic precursor cells from the somites into limb buds, diaphragm, and musculature; MET null mutants fail to populate limb muscles, leading to their absence. For -derived lineages, HGF/MET promotes the directed migration of precursors from the to the skin and other sites, with targeted disruption causing pigmentation defects due to failed colonization. These functions of MET are conserved in human embryonic development, with comparable expression patterns in fetal tissues driving organogenesis.

Role in Tissue Repair and Homeostasis

The hepatocyte growth factor receptor (MET), upon binding its ligand hepatocyte growth factor (HGF), plays a pivotal role in orchestrating tissue repair processes in adult organs by promoting cell proliferation, migration, and survival. In liver regeneration following partial hepatectomy, MET activation drives hepatocyte proliferation essential for restoring liver mass. HGF levels in plasma rise dramatically after injury, increasing approximately 10-fold within hours, which correlates with the initiation of regenerative signaling through MET to stimulate DNA synthesis and cell division in hepatocytes. This process is critical for compensatory growth, as evidenced by studies showing impaired regeneration in MET-deficient models post-hepatectomy. In the kidney, MET contributes to repair after acute injury by enhancing the recovery of tubular epithelial cells. Activation of MET by HGF provides anti-apoptotic protection, reducing cell death in proximal tubules exposed to ischemic or toxic insults and facilitating epithelial regeneration through pathways that inhibit caspase activation and promote cell survival. This renoprotective mechanism is particularly evident in models of acute kidney injury, where MET induction in tubular epithelium correlates with improved functional recovery and reduced fibrosis. MET also supports cardiac remodeling after by fostering and tissue repair. HGF/MET signaling promotes endothelial cell proliferation and vessel formation in the infarct border zone, aiding in the restoration of blood supply and limiting adverse . Recent studies from 2023 highlight how enhancing HGF/MET activity improves cardiac function post-infarction by reducing cardiomyocyte and supporting neovascularization. Beyond these organs, MET maintains epithelial integrity in the and , where it regulates barrier function and wound closure. In the GI mucosa, HGF/MET signaling preserves epithelial homeostasis by promoting and , countering injury-induced disruption. In , MET is essential for reepithelialization during acute , but its dysregulated expression—often spatially heterogeneous with upregulation at edges and downregulation in wound beds—contributes to impaired closure in chronic .

Pathological Roles

In Cancer

The hepatocyte growth factor receptor (MET) plays a pivotal oncogenic role in various cancers through genetic alterations such as amplification and , which lead to constitutive activation and drive formation. In gastric cancer, MET gene occurs in approximately 4-10% of cases, promoting uncontrolled and survival via downstream pathways like PI3K-Akt and MAPK. MET mutations are rare in gastric cancer but contribute to oncogenesis when present by enhancing activity. In (pRCC), somatic MET mutations are found in 13-15% of nonhereditary cases, often in the domain, activating the MET pathway and initiating tumorigenesis, while mutations underlie hereditary type 1 pRCC. MET activation significantly contributes to cancer progression by enhancing tumor , , and . The HGF/MET axis promotes epithelial-mesenchymal transition (EMT), enabling cancer cells to acquire migratory and invasive properties through signaling cascades involving ERK/Akt, Src, and FAK, as observed in cancers such as , colorectal, and . This pathway also upregulates (VEGF), fostering neovascularization essential for metastatic dissemination in primary and secondary tumors. Aberrant HGF/MET signaling is implicated in 20-30% of advanced solid tumors, where stromal-derived HGF from cancer-associated fibroblasts amplifies these processes. In therapeutic resistance, MET serves as a bypass mechanism, particularly in non-small cell lung cancer (NSCLC). MET amplification, occurring in 5-20% of EGFR inhibitor-resistant cases, activates ErbB3 and downstream PI3K/Akt signaling independently of EGFR, circumventing . Recent 2025 data further highlight MET's role in inhibitor (ICI) resistance in advanced NSCLC, where elevated plasma HGF levels correlate with disease progression (p=0.0092) by inhibiting CD8+ T-cell proliferation despite ; HGF/MET inhibitors like restore lymphocyte activation and IFNγ production, suggesting potential to overcome this barrier. High MET expression holds prognostic significance, notably in hepatocellular carcinoma (HCC), where it correlates with aggressive disease and poor outcomes. Patients with high c-MET protein expression exhibit significantly reduced 5-year survival rates (33.5%) compared to those with low expression (80.3%). In a phase II trial subset, MET-high HCC patients treated with tivantinib showed improved overall survival (7.2 months vs. 3.8 months ; HR=0.38, p=0.01), underscoring MET's impact on tumor aggressiveness.

In Other Diseases

The hepatocyte growth factor receptor (MET) has been implicated in several non-oncological disorders through genetic variants and dysregulated signaling. In autism spectrum disorder (ASD), promoter variants in the MET gene, particularly rs1858830, reduce MET expression in cortical , disrupting social brain circuitry and increasing ASD susceptibility. Initial genetic association studies from 2006 identified this variant's role in ASD risk across Caucasian and populations, with subsequent functional analyses up to 2023 confirming its impact on interneuron development and . In cardiovascular conditions, MET dysregulation contributes to heart failure progression, particularly post-myocardial . Elevated hepatocyte growth factor (HGF) levels correlate with severe and adverse prognosis, but HGF/MET activation promotes cardioprotection by enhancing , reducing , and improving after . MET plays a protective role in renal diseases such as . Elevated HGF protects podocytes by maintaining nephrin and WT1 expression, reducing and via PI3K/Akt-mediated restoration, and inhibiting through suppression of TGF-β signaling and epithelial-mesenchymal transition. Emerging research links the HGF/MET axis to and (CLL) survival. In non-malignant chronic liver conditions, HGF/MET signaling promotes regeneration and attenuates , aiding recovery from and injury. In CLL, the axis enhances leukemic cell survival by regulating anti-apoptotic pathways and microenvironment interactions, as demonstrated in a 2025 study identifying it as a potential non-oncological therapeutic target.

Molecular Interactions

With Tumor Suppressor Genes

The hepatocyte growth factor receptor (MET) interacts with tumor suppressor genes such as PTEN and VHL, modulating oncogenic signaling in specific cancers. In gliomas, loss of PTEN, a lipid and protein phosphatase, amplifies MET-driven activation of the PI3K/AKT pathway, promoting enhanced cell survival and proliferation. PTEN normally antagonizes PI3K signaling by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby preventing AKT recruitment and activation; however, in PTEN-deficient glioma cells, MET stimulation leads to hyperactivation of AKT, rendering cells hypersensitive to MET inhibition, which reduces AKT phosphorylation by approximately 30% and inhibits cell growth by 80-85%. Reconstitution of PTEN in these models suppresses AKT activity by over 80% and cell growth by 70-75%, underscoring the crosstalk where PTEN loss exacerbates MET-mediated survival signals. In (RCC), inactivation of the VHL tumor suppressor stabilizes hypoxia-inducible factor-1α (HIF-1α) by preventing its ubiquitination and degradation, leading to transcriptional upregulation of MET expression. This results in constitutive MET phosphorylation independent of its ligand HGF, even under normoxic conditions, driving uncontrolled cell growth and invasion in clear cell RCC. VHL reintroduction suppresses this MET hyperactivation, particularly at high cell densities where intercellular adhesion influences signaling. PTEN further antagonizes MET signaling by directly dephosphorylating AKT at key sites (T308 and S473), counteracting MET-induced AKT activation via its protein phosphatase activity. In clear cell RCC, PTEN loss occurs in approximately 16-20% of cases, potentiating PI3K/AKT hyperactivation and tumor progression. Experimental evidence from genetic mouse models demonstrates that combined MET overexpression and PTEN loss accelerates tumorigenesis. In hydrodynamic injection models of hepatocytes, PTEN knockout synergizes with c-MET overexpression to induce hepatocellular carcinomas as early as 9 weeks post-injection, with all mice developing multifocal tumors by 11-15 weeks, characterized by activated AKT/mTOR and Ras/MAPK pathways, increased proliferation (Ki67-positive), and metabolic reprogramming toward glycolysis and lipogenesis. This cooperative effect depends on intact mTORC2 signaling, as Rictor deletion (a mTORC2 component) abolishes tumor formation, highlighting how suppressor loss amplifies MET-driven oncogenesis.

With Other Proteins

The hepatocyte growth factor receptor (MET) engages in protein-protein interactions that modulate its localization, activation, and downstream effects, particularly through associations with , caveolin-1, co-receptors like , and regulatory ligases such as CBL. These interactions facilitate MET's role in cellular motility and trafficking without directly invoking tumor suppressor dynamics. MET binds to the α6β4 , forming a complex that enhances cell motility and invasion in response to growth factor (HGF). This association positions α6β4 as a signaling adapter, where the integrin's cytoplasmic domain recruits intracellular effectors to amplify MET-mediated invasive growth in cells. For instance, in epithelial cells, HGF stimulation promotes the recruitment of α6β4 to MET, thereby integrating cues with signaling to drive directional migration. MET interacts with caveolin-1 (CAV1), a principal component of caveolae, influencing receptor trafficking and localization within lipid rafts. Upon HGF stimulation, this interaction strengthens, leading to CAV1 and co-localization with MET at the plasma membrane, which modulates receptor internalization and sustains invasive signaling in cells. CAV1 thereby acts as a scaffold that fine-tunes MET's endocytic routing, potentially altering its availability for binding and promoting prolonged cellular responses. MET functions with co-receptors such as CD44v6 and RON to amplify HGF responsiveness. CD44v6 serves as a co-receptor by facilitating MET dimerization and activation; it binds HGF and recruits cytoskeletal adaptors like ERM proteins, enabling efficient signal propagation in epithelial and cells. Similarly, RON, a related , engages in crosstalk with MET through co-expression and shared signaling motifs, enhancing collective responses to ligands like HGF and macrophage-stimulating protein in tumor microenvironments. Negative regulation of MET occurs via ubiquitination mediated by the E3 ubiquitin ligase CBL, which targets tyrosine 1003 (Y1003) in the receptor's juxtamembrane domain. Phosphorylation of Y1003 recruits CBL, leading to polyubiquitination of MET and its subsequent endocytosis through clathrin-coated pits or caveolae-dependent pathways. This process directs MET to lysosomes for degradation, thereby attenuating prolonged signaling and maintaining homeostasis; mutations at Y1003 impair this ubiquitination, resulting in delayed receptor turnover.

Therapeutic Targeting

MET Kinase Inhibitors

MET kinase inhibitors are small-molecule drugs that target the intracellular kinase domain of the MET receptor , blocking its and downstream signaling activation. These inhibitors are primarily ATP-competitive and have been developed to treat MET-driven cancers, particularly non-small cell (NSCLC) harboring MET 14 skipping . Approved agents demonstrate high potency and selectivity, with clinical trials showing meaningful response rates in targeted patient populations. Capmatinib (Tabrecta), a selective type Ib ATP-competitive inhibitor, binds to the active (DFG-in) conformation of the MET domain, forming hydrogen bonds within the ATP-binding pocket to inhibit autophosphorylation. It exhibits an IC50 of 0.13 nM against wild-type MET and demonstrates over 10,000-fold selectivity compared to other receptor tyrosine kinases (RTKs) such as EGFR, VEGFR2, and RON. The U.S. (FDA) granted accelerated approval to in May 2020 for adult patients with metastatic NSCLC whose tumors have MET 14 skipping mutations, as detected by an FDA-approved test; regular approval followed in August 2022 based on confirmatory data. In the phase II GEOMETRY mono-1 trial, achieved an objective response rate (ORR) of 68% (95% CI: 48-84) in treatment-naïve patients with MET 14 skipping NSCLC, with a median duration of response of 9.7 months and median of 12.6 months. Updated analyses from 2021 confirmed sustained efficacy, with an ORR of 65.6% in this cohort. Tepotinib (Tepmetko), another type Ib ATP-competitive MET inhibitor, similarly targets the active conformation with high selectivity, inhibiting MET with IC50 values of 1.7-1.8 nM in biochemical assays and showing minimal activity against a panel of 230-300 s at concentrations up to 1 μM. It possesses greater than 1,000-fold selectivity over other RTKs, including ALK, ROS1, and . The FDA granted accelerated approval to tepotinib in February 2021 and traditional approval in February 2024 for adult patients with metastatic NSCLC harboring MET 14 skipping mutations. The phase II VISION trial reported an ORR of 46% (95% CI: 39-54) overall, rising to 57.3% in patients with high-confidence MET 14 mutations confirmed by or tissue , with a median duration of response of 11.1 months and median of 8.5 months; long-term follow-up through 2023 maintained these outcomes, including an ORR of 58.6% in treatment-naïve subgroups. Despite initial efficacy, resistance to MET inhibitors like capmatinib and tepotinib often develops through on-target mechanisms, including secondary MET domain that alter inhibitor binding. The solvent-front G1163R, for instance, emerges post-treatment and reduces sensitivity by sterically hindering access to the ATP site, particularly impacting type I inhibitors; preclinical models show it confers resistance to capmatinib and tepotinib, necessitating sequential use of alternative agents such as type II inhibitors. Other common resistance alterations include D1228N and Y1230C/H, which similarly impair drug efficacy in MET exon 14-mutated NSCLC. Clinical data from 2023-2025 trials, including post-progression analyses, indicate that approximately 20-30% of resistant cases harbor such , highlighting the need for mutation-specific next-line therapies.

HGF and MET Antagonists

Antagonists targeting hepatocyte growth factor (HGF) or the MET receptor extracellularly represent a class of therapeutics designed to block ligand-receptor interactions, thereby inhibiting MET signaling without directly affecting the intracellular domain. These include monoclonal antibodies that neutralize HGF or bind MET to prevent dimerization and activation, as well as decoy receptors that trap HGF as ligand sinks. Unlike small-molecule inhibitors, these agents focus on extracellular blockade, offering potential advantages in selectivity and reduced off-target effects in normal tissues expressing MET. Preclinical and clinical studies have explored their efficacy in MET-driven malignancies, particularly where HGF/MET axis hyperactivity promotes tumor growth, , and . Anti-HGF antibodies, such as ficlatuzumab and rilotumumab, sequester HGF to inhibit its binding to MET. Ficlatuzumab, a humanized IgG1 monoclonal antibody, binds with high affinity to both pro-HGF and mature HGF, neutralizing the ligand and preventing proteolytic activation and subsequent MET stimulation. In a randomized phase II trial for pan-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), ficlatuzumab monotherapy yielded a median progression-free survival (PFS) of 1.8 months and objective response rate (ORR) of 4%, while combination with the EGFR inhibitor cetuximab improved median PFS to 3.7 months (P=0.04) and ORR to 19%, with enhanced responses in HPV-negative (ORR 38%, P=0.02) and c-Met-overexpressing subgroups, suggesting synergistic pathway inhibition. A phase III trial evaluating ficlatuzumab plus cetuximab is ongoing in similar HNSCC populations. Rilotumumab, another humanized monoclonal antibody, specifically targets mature HGF to block its interaction with MET. In the phase III RILOMET-1 trial for advanced MET-positive gastric or gastro-oesophageal junction cancer, rilotumumab combined with epirubicin, cisplatin, and capecitabine failed to improve overall survival (median 8.8 months vs. 10.7 months; hazard ratio 1.34, P=0.003) and was halted early due to increased mortality in the treatment arm, with no benefits observed across subgroups defined by MET expression or HGF levels. Despite earlier phase II signals of PFS extension in MET-high gastric cancer, rilotumumab development has been discontinued following these results. Anti-MET antibodies and decoy constructs directly engage the receptor to disrupt HGF-induced dimerization. Onartuzumab (MetMAb), a monovalent humanized antibody, binds the Sema domain (specifically blades 4–6) of MET, sterically hindering HGF association and receptor activation while avoiding agonistic effects through its monovalent design. The phase III METLUNG trial in previously treated MET-positive non-small cell lung cancer (NSCLC) randomized patients to onartuzumab plus erlotinib versus erlotinib alone, but showed no overall survival benefit (median 6.8 months vs. 9.1 months; hazard ratio 1.27, P=0.068) or PFS improvement (2.7 months vs. 2.6 months), leading to trial discontinuation for futility in 2014. Development of onartuzumab was subsequently halted due to these negative outcomes. Decoy MET approaches, exemplified by DN30 and its derivatives, utilize antibody-mediated receptor shedding or soluble extracellular fragments to deplete surface MET or trap HGF. The DN30 monoclonal antibody binds the IPT-4 domain of MET, triggering ADAM-10-dependent proteolytic shedding that reduces cell-surface receptor levels by up to 57% and inhibits HGF-induced phosphorylation, migration, and invasion in preclinical models. In vivo, DN30 suppresses primary tumor growth and spontaneous metastasis formation in MET-dependent xenografts, such as gastric and lung carcinoma models, with efficacy enhanced in humanized formats like hOA-DN30 that promote MET degradation and tumor remission. Soluble decoy MET fragments, such as C-terminal constructs or DN30-derived Fabs, further act as HGF traps, demonstrating preclinical antitumor activity in metastasis assays by sequestering ligand and preventing signaling. These decoy strategies remain primarily investigational, with ongoing efforts to improve pharmacokinetics for clinical translation.

Emerging Therapies

Passive immunotherapy strategies targeting the hepatocyte growth factor receptor (MET) have advanced into early clinical stages, focusing on bispecific antibodies and antibody-drug conjugates (ADCs) to enhance specificity and in MET-overexpressing solid tumors. Emibetuzumab (LY2875358), a bivalent humanized IgG4 , binds to MET with high affinity, blocking hepatocyte growth factor (HGF) binding and inducing receptor internalization and lysosomal degradation, thereby inhibiting both ligand-dependent and independent MET signaling. In phase I trials, emibetuzumab monotherapy was well-tolerated in patients with advanced solid tumors at doses up to 2000 mg, demonstrating preliminary antitumor activity, particularly in MET-amplified non-small cell (NSCLC). Ongoing phase II evaluations, including combinations with , continue to explore its role in EGFR-mutant NSCLC, with 2025 updates confirming stable disease in subsets of MET-dysregulated patients. Antibody-drug conjugates represent another passive approach, linking MET-targeting to cytotoxic payloads for targeted delivery. SHR-1826, a novel c-MET-directed ADC, has entered phase I testing in advanced solid tumors, showing dose-dependent tumor regression in preclinical models and manageable safety in initial human cohorts as of 2025. Similarly, ABBV-400, an ADC conjugating a MET-specific to a I inhibitor payload, demonstrated encouraging responses in MET-amplified colorectal and other solid tumors in phase I studies, with objective response rates around 20% in heavily pretreated patients. Active immunotherapy modalities, such as chimeric antigen receptor () T cells targeting MET, offer promise for eliciting durable responses against MET-expressing malignancies. Preclinical studies have validated MET-specific CAR-T cells in suppressing tumor growth in MET-overexpressing models of NSCLC and (HCC), with enhanced cytotoxicity observed through co-expression of dominant-negative TGF-β receptors to counter immunosuppressive signals. In (CLL), where HGF/MET signaling supports leukemic cell survival via anti-apoptotic pathways, targeting this axis with immunotherapies like CAR-T holds potential, supported by 2025 preclinical data indicating reduced CLL proliferation upon MET inhibition. MET vaccines remain largely investigational, with limited clinical translation to date. Combination therapies integrating MET inhibition with immune checkpoint inhibitors (ICIs) address resistance mechanisms in NSCLC, where HGF/MET activation promotes an immunosuppressive and limits PD-1/PD-L1 blockade efficacy. A 2025 analysis revealed elevated HGF/MET signaling in ICI-resistant advanced NSCLC tumors, correlating with poorer ; dual inhibition restored T-cell infiltration and enhanced response rates in preclinical models. Clinical trials combining MET inhibitors like with PD-1 blockers (e.g., ) in MET-altered NSCLC, such as the phase II study in treatment-naïve PD-L1-high patients, did not demonstrate improved efficacy over alone, highlighting challenges in this approach. Other MET TKIs, such as savolitinib and glumetinib, have received approval in for MET 14 skipping NSCLC as of 2025, expanding global options for . Inhibitors of pro-HGF activation and gene-based therapies represent cutting-edge strategies to disrupt upstream MET signaling in specific contexts like . Pro-HGF activator inhibitors (HGFA-I), such as SRI31215, block the conversion of inactive pro-HGF to its bioactive form, reducing MET-driven invasion in fibroblast-rich tumor microenvironments; combined with MET inhibitors, this approach yielded significant tumor reduction in castration-resistant models in 2025 studies. /Cas9-mediated MET knockdown has demonstrated therapeutic potential in models, including HCC, where MET overexpression cooperates with TP53 loss to drive tumorigenesis—gene editing reduced tumor burden and progression in preclinical xenografts. These combined modalities highlight opportunities for precision interventions in HGF/MET-dependent pathologies.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4156285/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3225017/
  3. https://www.nature.com/articles/s41467-021-24367-3
  4. https://www.biochempeg.com/article/435.html
  5. https://www.ncbi.nlm.nih.gov/gene/4233
  6. https://pubmed.ncbi.nlm.nih.gov/9380410/
  7. https://pubmed.ncbi.nlm.nih.gov/9484774/
  8. https://atlasgeneticsoncology.org/gene/131/met-met-proto-oncogene-%28hepatocyte-growth-factor-receptor%29
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4340422/
  10. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MET
  11. https://www.nature.com/articles/ng0597-68
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5451609/
  13. https://www.mdpi.com/2072-6694/17/9/1493
  14. https://pubmed.ncbi.nlm.nih.gov/37451931/
  15. https://www.sciencedirect.com/science/article/pii/S2666364325000426
  16. https://www.embopress.org/doi/full/10.1038/sj.emboj.7600243
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2475716/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8711257/
  19. https://www.sciencedirect.com/science/article/pii/S1535610804001801
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8990287/
  21. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00490/full
  22. https://pubmed.ncbi.nlm.nih.gov/8302603/
  23. https://www.pnas.org/doi/10.1073/pnas.1734128100
  24. https://gtexportal.org/home/gene/ENSG00000105976
  25. https://academic.oup.com/jcem/article/82/3/949/2656690
  26. https://pubmed.ncbi.nlm.nih.gov/15153617/
  27. https://genesdev.cshlp.org/content/16/23/3074.full.html
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3116738/
  29. https://academic.oup.com/carcin/article/37/4/345/2365816
  30. https://www.sciencedirect.com/science/article/pii/S0021925820637152
  31. https://www.sciencedirect.com/science/article/pii/S1535610803000850
  32. https://aacrjournals.org/cancerres/article/69/19/7569/550039/MicroRNA-34a-Inhibits-Glioblastoma-Growth-by
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4617658/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3028638/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC6275078/
  36. https://reactome.org/content/detail/R-HSA-6806942
  37. https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/slct.202301577
  38. https://www.life-science-alliance.org/content/5/10/e202201409
  39. https://doi.org/10.1083/jcb.149.7.1419
  40. https://reactome.org/content/detail/R-HSA-8851804
  41. https://doi.org/10.1038/sj.onc.1205004
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3666747/
  43. https://www.nature.com/articles/srep14301
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC384772/
  45. https://www.nature.com/articles/373699a0
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2862758/
  47. https://journals.biologists.com/dev/article/125/7/1315/40192/Hepatocyte-growth-factor-HGF-acts-as-a-mesenchyme
  48. https://pubmed.ncbi.nlm.nih.gov/8631159/
  49. https://pubmed.ncbi.nlm.nih.gov/10193678/
  50. https://onlinelibrary.wiley.com/doi/10.1155/2011/869281
  51. https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840130422
  52. https://www.pnas.org/doi/10.1073/pnas.0403412101
  53. https://journals.physiology.org/doi/10.1152/ajprenal.1999.277.4.F624
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3758808/
  55. https://jbioleng.biomedcentral.com/articles/10.1186/s13036-023-00330-2
  56. https://www.sciencedirect.com/science/article/abs/pii/S0923181104002592
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2064119/
  58. https://www.mdpi.com/2227-9059/11/12/3172
  59. https://www.nejm.org/doi/full/10.1056/NEJMoa1505917
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC5344235/
  61. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0759-9
  62. https://pubmed.ncbi.nlm.nih.gov/39751636/
  63. https://aacrjournals.org/clincancerres/article/19/9/2310/78201/Targeting-the-HGF-c-MET-Pathway-in-Hepatocellular
  64. https://www.nature.com/articles/ejhg2008215
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC2678909/
  66. https://gene.sfari.org/database/human-gene/met
  67. https://www.jacc.org/doi/10.1016/j.jacadv.2025.101828
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC5344277/
  69. https://www.kidney-international.org/article/S0085-2538%2815%2954167-7/fulltext
  70. https://www.nature.com/articles/s41598-018-31121-1
  71. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.808855/full
  72. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1612916/full
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3164392/
  74. https://aacrjournals.org/cancerres/article/66/7/3699/527523/Inactivation-of-von-Hippel-Lindau-Gene-Induces
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC8273154/
  76. https://www.auajournals.org/doi/10.1016/j.juro.2014.03.097
  77. https://www.nature.com/articles/emm2017158
  78. https://www.sciencedirect.com/science/article/pii/S0092867401005670
  79. https://pubmed.ncbi.nlm.nih.gov/11733063/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4141763/
  81. https://genesdev.cshlp.org/content/16/23/3074
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC187488/
  83. https://www.oncotarget.com/article/3420/text/
  84. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0796-y
  85. https://www.sciencedirect.com/science/article/pii/S1097276501003781
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC1265818/
  87. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.11-197723
  88. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer
  89. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC10377299/
  91. https://tlcr.amegroups.org/article/view/49717/html
  92. https://aacrjournals.org/mct/article/22/7/833/727412/The-Preclinical-Pharmacology-of-Tepotinib-A-Highly
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC10320478/
  94. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01299-z
  95. https://aacrjournals.org/clincancerres/article/26/11/2615/284531/Molecular-Mechanisms-of-Acquired-Resistance-to-MET
  96. https://www.jto.org/article/S1556-0864%2821%2901735-4/fulltext
  97. https://pubmed.ncbi.nlm.nih.gov/27803065/
  98. https://journals.sagepub.com/doi/10.1177/17588359241290733
  99. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.106
  100. https://www.hematologyandoncology.net/archives/september-2025/the-emerging-role-of-antibody-drug-conjugates-in-metastatic-colorectal-cancer/
  101. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04521-9
  102. https://link.springer.com/article/10.1007/s00262-024-03882-4
  103. https://www.sciencedirect.com/science/article/pii/S0305737225001124
  104. https://pubmed.ncbi.nlm.nih.gov/40076928/
  105. https://www.nature.com/articles/s41419-023-05958-y
Add your contribution
Related Hubs
User Avatar
No comments yet.